Vitamin D Receptor Activation and Left Ventricular Hypertrophy in Advanced Kidney Disease
Ravi Thadhani, Evan Appelbaum, Yuchiao Chang, Yili Pritchett, Ishir Bhan, Rajiv Agarwal, Carmine Zoccali, Christoph Wanner, Donald Lloyd-Jones, Jorge Cannata, Taylor Thompson, Paul Audhya, Dennis Andress, Wuyan Zhang, Jun Ye, David Packham, Bhupinder Singh, Daniel Zehnder, Warren J Manning, Ajay Pachika Show all
AMERICAN JOURNAL OF NEPHROLOGY | KARGER | Published : 2011
BACKGROUND: In chronic kidney disease (CKD), left ventricular hypertrophy (LVH) is prevalent and is associated with increased cardiovascular morbidity and mortality. Vitamin D receptor (VDR) activation attenuates LVH progression in animal models. METHODS: PRIMO is a multinational, randomized, double-blinded trial with oral paricalcitol in subjects with stages 3-4 CKD, mild-to-moderate LVH and an LV ejection fraction >50%. The primary endpoint is change in the left ventricular mass index (LVMI) compared with placebo after 48 weeks of treatment. The main secondary endpoints are changes in diastolic function parameters. In this paper, we report baseline characteristics from this study. RESULTS:..View full abstract
Awarded by NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES
R.T. is supported by a research grant from Abbott Laboratories. R.A. has received honoraria for serving on the speaker's bureau and steering committees of Abbott Laboratories. C.W. serves on an advisory board for Abbott and has received research support, speakers fees and travel support from Abbott. Y.P., P.A. and D.A. are employees of Abbott Laboratories.